47 completed, 31 recruiting, 29 terminated, 20 unknown. 76 Phase 1, 54 Phase 2, 20 Not applicable, 6 Phase 3, 3 Phase 4.
Follow Non Hodgkin Lymphoma: new trials by email Literature Review of Non Hodgkin Lymphoma trials Research Report on Non Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Pre-malignant States to Hematologic Malignancies in Firefighters Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP) - Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy | Recruiting | Wake Forest University Health Sciences | 300 | 2026-06-23 | 2026-07-13 | |
| SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas SB-4826, Rituximab - Non Hodgkin Lymphoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of California, San Diego | 48 | 2026-02-18 | 2026-03-05 |
| Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK - Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2026-02-01 | 2026-02-18 |
| Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford Neuropsychological testing - Non Hodgkin Lymphoma | Not applicable | Withdrawn | Stanford University | 2025-12-01 | 2026-06-24 | |
| A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. Omeprazole, Dextromethorphan - Hodgkin Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Murdoch Childrens Research Institute | 10 | 2025-07-22 | 2026-08-27 |
| Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy GOLCADOMIDE, Nivolumab - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | University of Pittsburgh | 2025-06-30 | 2026-04-13 | |
| Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Recruiting | Gadjah Mada University | 120 | 2025-06-01 | 2025-08-22 |
| A Study to Evaluate the Safety and Clinical Efficacy of STR-P004 STR-P004 - Non Hodgkin Lymphoma | Early Phase 1 | Not yet recruiting | Starna Therapeutics | 30 | 2025-06-01 | 2025-06-04 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL Iomab-B, CAR-T cell - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 30 | 2025-04-25 | 2026-05-08 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-02-06 | 2026-08-06 |
| A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma ONO-7018 - Non Hodgkin Lymphoma | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 2 | 2024-11-27 | 2026-07-29 |
| PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy 64Cu-GRIP B, Positron Emission Tomography (PET), Optional tumor biopsy - Non Hodgkin Lymphoma | Phase 1 | Recruiting | Michael Randall | 32 | 2024-10-23 | 2025-12-29 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| Impact of Respiratory Training in Lymphoma Survivors Inspiratory muscle strength training, Sham Inspiratory muscle strength training - Hodgkin Lymphoma, Non Hodgkin Lymphoma | Not applicable | Terminated | University of Colorado, Denver | 1 | 2024-09-16 | 2026-02-27 |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU Long-term Follow-Up - Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting | Miltenyi Biomedicine GmbH | 150 | 2024-05-15 | 2026-08-05 | |
| AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) ARROW strategies, One-time education - Cervical Cancer, Kaposi Sarcoma | Not applicable | Recruiting | Implenomics | 4100 | 2024-05-01 | 2026-11-04 |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies TGRX-814 - Hematologic Malignancy, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Shenzhen TargetRx Co., Ltd. | 30 | 2024-03-06 | 2024-04-10 |
Showing 20 of 156. Sign in to see all of them.
Lymphoma, Non-Hodgkin (156) · Hodgkin Disease (36) · Leukemia, Lymphocytic, Chronic, B-Cell (28) · Leukemia, Myeloid, Acute (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Lymphoma, Follicular (22) · Multiple Myeloma (22) · Lymphoma, Large B-Cell, Diffuse (19) · Myelodysplastic Syndromes (18) · Lymphoma (16) · Lymphoma, B-Cell (16) · Lymphoma, Mantle-Cell (15) · Leukemia (13) · Lymphoma, B-Cell, Marginal Zone (12) · Neoplasms (12)
Hemic and Lymphatic Diseases (156) · Immune System Diseases (156) · Immunoproliferative Disorders (156) · Lymphatic Diseases (156) · Neoplasms by Histologic Type (156) · Lymphoproliferative Disorders (155) · Neoplasms (144) · Lymphoma (140) · Hematologic Diseases (62) · Leukemia (47) · Pathologic Processes (47) · Pathological Conditions, Signs and Symptoms (47) · Leukemia, Lymphoid (43) · Disease Attributes (39) · Chronic Disease (36)
Cyclophosphamide (23) · Rituximab (15) · fludarabine (13) · fludarabine phosphate (8) · Mycophenolic Acid (7) · Bendamustine Hydrochloride (4) · Interleukin-2 (4) · Tacrolimus (4) · Whole-Body Irradiation (4) · acalabrutinib (4) · venetoclax (4) · Azacitidine (3) · Blood Specimen Collection (3) · Cyclosporine (3) · Filgrastim (3)
Wake Forest University Health Sciences (4) · Baylor College of Medicine (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Stanford University (3) · University of Colorado, Denver (3) · Ascentage Pharma Group Inc. (2) · Case Comprehensive Cancer Center (2) · Centre Leon Berard (2) · Chongqing Precision Biotech Co., Ltd (2) · Copenhagen University Hospital, Rigshospitalet (2) · David Wald (2) · Fondazione Italiana Linfomi - ETS (2) · Huiqiang Huang (2) · Institut Paoli-Calmettes (2) · MEI Pharma, Inc. (2)
United States (82) · China (25) · France (21) · Australia (14) · Italy (12) · Spain (11) · United Kingdom (11) · Belgium (9) · Poland (9) · South Korea (6) · Germany (5) · Taiwan (5) · Denmark (4) · Canada (3) · Czechia (3)
Arnon Nagler, MD (2) · Benjamin Tomlinson, MD (2) · Helen E Heslop, MD (2) · Jianxiang Wang, MD (2) · A. Paz Coll, MD (1) · A. Salar, MD (1) · Akhil Kumar, MD (1) · Alessandro Rambaldi, MD (1) · Amir A Toor, MD (1) · Andy Davies (1) · Ann LaCasce, MD (1) · Arturo Molina, MD (1) · Ashley Rogers (1)
PMID 34515338, PMID 21454450, PMID 30262660, PMID 15770833, PMID 17609424, PMID 20671118, PMID 23317527, PMID 23812930, PMID 23834234, PMID 24344220, PMID 24831981, PMID 25977584, PMID 26183076, PMID 26883583, PMID 27217449, PMID 29149611, PMID 31444250, PMID 31554370, PMID 33632155, PMID 33956213, PMID 36166003, PMID 36585130, PMID 37202143, PMID 37224793, PMID 37848259, PMID 38297229, PMID 39213421, PMID 39293083, PMID 39479329, PMID 39571113, PMID 39854647, PMID 39923848, PMID 39928957, PMID 40055982, PMID 40259519, PMID 40423982, PMID 40442628, PMID 41136989, PMID 42242517, PMID 42545812, PMID 42782312, PMID 42784255
2017 (3), 2016 (1), 2018 (1), 2019 (1), 2023 (1), P01CA015396 (1), P01CA111412 (1), P30CA012197 (1), R01CA226078 (1), R33CA226960 (1), UL1TR002240 (1)